Genetic Analysis of Papillary Thyroid Tumors Using Mass-ARRAY Technology to Understand Mutation Profiles and Patient Outcomes

What this Trial Is About

Researchers are studying papillary thyroid cancer PTC to understand the genetic mutations present in these tumors, especially in the MAP kinase pathway. The study aims to analyze the mutational profile of many PTC tumors to help predict patient prognosis and how targeted treatments might work. This research uses a specialized technology called Mass ARRAY to identify common genetic changes in PTCs in a quick and cost-effective way. The study involves analyzing tumor samples from patients with papillary thyroid cancer using the PTC-MA platform. This platform detects multiple key mutations and rearrangements in the cancer cells through genetic testing called genotyping. The study is observational, focusing on collecting and characterizing genetic information without administering treatments. Participants provide tumor tissue samples that researchers examine for genetic mutations. The team will correlate these molecular profiles with the patients clinical features and outcomes over a period of up to eight years. The main outcome measured is the mutational profile of the PTC tumors. There is no intervention beyond genetic testing, and participants are monitored through their usual clinical care.

Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY